Dyne Therapeutics Reports Officer and Director Changes
Ticker: DYN · Form: 8-K · Filed: Oct 2, 2025 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $12.50, $45,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, officer-appointment, director-election, compensation
Related Tickers: DYNE
TL;DR
DYNE leadership shakeup: new officers elected, directors potentially out, comp plans updated.
AI Summary
Dyne Therapeutics, Inc. filed an 8-K on October 2, 2025, reporting changes effective October 1, 2025. The filing indicates a departure of directors or certain officers, election of directors, appointment of certain officers, and updates to compensatory arrangements for certain officers. Specific details regarding the individuals involved and the nature of these changes are not provided in this excerpt.
Why It Matters
Changes in key leadership and compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and director roles, especially without immediate detailed explanation, can introduce uncertainty regarding company direction and stability.
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — Registrant
- October 1, 2025 (date) — Effective date of reported changes
- October 2, 2025 (date) — Filing date of the 8-K
FAQ
What specific roles have changed for officers and directors at Dyne Therapeutics?
The filing indicates changes in 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but does not specify the individuals or their exact role changes in this excerpt.
Are there any details on the new compensatory arrangements for officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item being reported, but the specific details of these arrangements are not included in this provided text.
When were these changes officially effective?
The earliest event reported is dated October 1, 2025.
What is the primary business of Dyne Therapeutics?
Dyne Therapeutics, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
Where is Dyne Therapeutics headquartered?
Dyne Therapeutics, Inc. is headquartered at 1560 Trapelo Road, Waltham, Massachusetts 02451.
Filing Stats: 739 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-10-02 16:10:27
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share DYN Nasdaq Glob
- $12.50 — mon stock at an exercise price equal to $12.50 per share, the closing price of the Com
- $45,000 — ill receive annual cash compensation of $45,000 as a member of the Board, annual equity
Filing Documents
- dyn-20251001.htm (8-K) — 54KB
- 0001193125-25-228317.txt ( ) — 163KB
- dyn-20251001.xsd (EX-101.SCH) — 30KB
- dyn-20251001_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: October 2, 2025 By: /s/ John G. Cox Name: John G. Cox Title: President and Chief Executive Officer